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Background: Emerging evidence has shown that miRNAs are involved in human carcinogenesis as tumor
suppressors or oncogenes. Single nucleotide polymorphisms (SNPs) located in pre-miRNAs may affect the
processing and therefore, influence the expression of mature miRNAs. Previous studies generated conflicting results
when reporting association between the hsa-miR-196a2 rs11614913 common polymorphism and breast cancer.
Methods: This study evaluated the hsa-miR-196a2 rs11614913 SNP in 388 breast cancer cases and 388 controls in
Brazilian women. Polymorphism was determined by real-time PCR; control and experimental groups were
compared through statistical analysis using the X2 or Fisher’s exact tests.
Results: The analysis of the SNPs frequencies showed a significant difference between the groups (BC and CT) in
regards to genotype distribution (χ2: p = 0.024); the homozygous variant (CC) was more frequent in the CT than in
the BC group (p = 0.009). The presence of the hsa-miR-196a2 rs11614913 C/T polymorphism was not associated
with histological grades (p = 0.522), axillary lymph node positive status (p = 0.805), or clinical stage (p = 0.670)
among the breast cancer patients.
Conclusions: The results of this study indicated that the CC polymorphic genotype is associated with a decreased
risk of BC and the presence of the T allele was significantly associated with an increased risk of BC.
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MiRNAs represent a recently discovered class of small
regulatory RNAs that influence the stability and effi-
ciency of target mRNAs and are implicated in a growing
number of biological processes including neoplasms. Re-
cent studies have demonstrated the involvement of these
regulatory molecules in the development of breast can-
cer (BC) [1].* Correspondence: juvenalinhares@gmail.com
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reproduction in any medium, provided the orZhang et al. compared the expression patterns of miR-
NAs between healthy and BC mammary tissues and
observed, preliminarily, that various miRNAs are
expressed in different ways in BC. This observation lead
to the hypothesis that expression profiles of miRNAs
could be correlated with special tumor phenotypes or
associated with tumor suppression or tumorigenesis [2].
Iorio et al., using microarray analysis, demonstrated that
aberrant expression of miRNAs is associated with
human BC [3].
MiRNAs have an enormous potential as biomarkers of
BC because their expression is known to be aberrant in
cancer with pathognomonic profiles, that is, related to
specific tissues; in addition, they are notably stable mole-
cules that remain well preserved in formalin, paraffin-
embedded tissues, and fresh or frozen tissues [4,5].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and risk of cancer has been established and, thus pro-
vides supporting pathways for the investigation of mo-
lecular mechanisms involved in the development of
cancer. The loss or gain of function of particular miR-
NAs are also involved in events during the genesis of
various types of cancer, including BC [6]. For example,
hsa-mir-10B has been identified as an initiator of inva-
sion and metastasis in BC [7], where expression patterns
are altered in human BC [3,8].
Because BC is an estrogen-dependent tumor, mechan-
isms involving the estrogen receptor have been consid-
ered in studies addressing the molecular understanding
of this disease. Estrogen receptors have been recently
shown to be regulated by miRNAs as well as other
cofactors. miRNAs are regulatory RNA molecules that
have been foremost in the molecular investigation of
many diseases and cellular processes. They exert their
effect directly on target genes resulting in transcriptional
repression or degradation of the target sequence [9,10].
The hsa-miR-196a2 rs11614913 polymorphism, located
on chromosome 12 (12q13.13), appears to regulate the
Hox gene in a subgroup of the homeobox genes. This
subgroup controls the development and positional dif-
ferentiation of cells in the embryo. Thus, the prediction
of the miRNAs that would target homeobox genes
(together with genes that have an important function in
development through the control of the parts of the
embryo that will develop into organs and specific tissues)
seem to be an especially attractive area for the investi-
gation of breast cancer development [11].
The modulation of the p53 gene expression is con-
troled by HOX proteins that bind to its promoter region
[12,13]. In addition, the expression of these proteins can
lead to inhibition of p53-dependent apoptosis in BC
cells. Therefore, the decreased gene expression in mam-
mary tumors can act on p53, firstly through the promo-
tion of genome instability, and secondly through
opposing mechanisms that lead to apoptosis there
after [10,12,14].
In a case–control study with Chinese women with
breast cancer, the genotype variant of hsa-miR-196a2
rs11614913 was associated with a significantly increased
risk of BC [15].That study provided the first evidence
that SNPs, common in miRNAs, could be utilized as
candidate biomarkers for BC susceptibility.
A recent case–control study with Italian and German
women that evaluated miRNAs polymorphisms showed
that the hsa-miR-196a2 rs11614913 genotype was not
associated with increased risk of BC [16].
The correlations between the hsa-miR-196a2 rs11614913
C/T SNP and development of breast cancer are con-
troversially reported in the literature. Moreover, there
are no relevant studies in South American populationsreporting on this subject. Hence, this study assessed
the presence of hsa-miR-196a2 rs11614913 polymor-
phisms in microRNA sequences from Brazilian women
with and without breast cancer and its association with
breast cancer.Methods
Subjects
The Research Ethics Committee from the Federal Uni-
versity of Sao Paulo (No. 0211/08) approved this study;
signed informed consents were obtained from all partici-
pants before the study start. The study included 388
women diagnosed between April 2004 and July 2010
with invasive ductal breast carcinoma (BC group) in the
Mastology Division of the “Francisco Morato Oliveira”
Hospital (HSPE-FMO) and Federal University of São
Paulo (UNIFESP-EPM) in Brazil. The diagnosis of breast
carcinoma was reached through clinical and radiological
examinations (mammography and/or ultrasonography)
and subsequently confirmed by the histopathological as-
sessment of biopsies. Peripheral blood samples were col-
lected regardless of the clinical stage or previous
treatment. Pregnant women or patients under hormonal
therapy (HT) were excluded from the study.
The control group (CT group) included samples of
oral mucosal scrapings obtained from 388 women with-
out breast cancer attending the Menopause and
Gynecology Clinic for routine consultations at the same
institutions mentioned above. These patients were also
screened for breast cancer through clinical and radio-
logical examinations (mammography and/or ultrasound);
patients under hormonal therapy (HT), pregnant, or
with a prior history of breast biopsy were excluded. The
oral samples from these patients were collected using a
CytobrushW and stored in dry tubes.
Data from all patients were collected in a standardized
form containing information about age, race (Caucasianor-
non-Caucasian), age at menarche (under or over 12 years
of age), pre or post-menopausal status, family history of
breast cancer (first-degree relative: mother, sister, or daugh-
ter), the habit of smoking, cancer clinical stage, axillary
lymph node status, and Scarff-Bloom-Richardson (SBR)
histological grade.Genotyping
DNA was extracted from blood and oral mucosal scrap-
ping samples according to the protocol for the GFXW kit
for cells, tissues, and blood (Amersham-Pharmacia).
The hsa-miR-196a2 rs11614913 C/T SNP was geno-
typed using the Custom TaqManW SNP Genotyping
Assays (Applied Biosystems, ID C_31185852_10). Be-
tween 1 and 20 ng of DNA was used per PCR reaction
performed in duplicates at the final volume of 20 ul
Table 1 Summary of demographic characteristics and risk
factors for breast cancer development
VARIABLE CT group
(n = 388)
BC group
(n = 388)
p value
Age in years (mean ± SD) 55.1 ± 10.3 57.7 ± 12.6 0.008
Age at menarche in years 12.9 ± 1.6 13.0 ± 1.6 0.700
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(Applied BiosystemsW).
The cycling conditions were 50°C for 2 min, 95°C
for 10 min, 40 cycles of at 92°C for 15 s, and annealing/
extension at 60°C for 1 min. The data were analyzed
using the SDS Software v. 1.3.1.(mean ± SD)
Race
Caucasian 19.4% 16.2% <0.001
Non-Caucasian 70.6% 83.8%
Patients at Menopause 66.8% 63.9% 0.225
Habit of smoking 26.3% 22.4% 0.240
First-degree family history
of breast cancer
16.7% 18.0% 0.635
Histological Grade
1 —— 24.5% ——
2 —— 47.9% ——
3 —— 27.6% ——
Clinical stages
1 —— 34.5% ——
2 —— 43.8% ——
3 —— 16.0% ——
4 —— 5.7% ——Statistical analysis
The outcomes were analyzed taking into consideration
the patients’ characteristics assessed in the standardized
form used for data collection. First-degree relatives such
as mother, sisters, or daughters were considered in the
assessment of family history of breast cancer.
The demographic characteristics of the groups were
compared by the Student's t-test for continuous variables
and the qui-squared test (χ2) for nominal variables. The
Pearson’s chi-square test was used to assess the correl-
ation between variables; multiple linear and logistic re-
gression models were used to evaluate associations
between genotypes, alleles, and occurrence of breast
cancer. The CC genotype was considered as the refer-
ence for comparisons with the TC (heterozygote) and
TT (homozygote) variants. The sample power was calcu-
lated based on the proportion of patients with at least
one mutated allele (TC or TT). The sample power in
this study was 0.77 considering an alpha error = 0.05.
The SPSS 15 statistical software was used for data ana-
lyses and a p value ≤ 0.05 was considered statistically
significant.Table 2 Genotype distribution in the CT and BC groups
GROUPS Genotype HWE
CC TC TT
CT Count 127 165 96 0.004
% within Group 32.7% 42.5% 24.7%
BC Count 94 177 117 0.096
% within Group 24.2% 45.6% 30.2%
HWE: Hardy-Weinberg Equilibrium.χ2: p = 0.024.Results
The demographic characteristics and risk factors asso-
ciated with the BC and CT groups are shown in Table 1.
The BC group presented an average age that was
2.6 years older than the CT group and a higher percent-
age of non-Caucasian patients. Axillary lymph node
positive status was observed in 45.8% of the patients in
the BC group; breast cancer histological grades and clin-
ical stages are shown in Table 1.
The genotype distribution in the CT and BC groups
are shown in Table 2; 100% concordance was observed
between the results from the samples’ duplicates. The
analysis of the frequencies showed a significant differ-
ence in genotype distribution between groups (BC and
CT) (χ2: p = 0.024); the homozygous variant (CC) was
more frequent in the CT group than in the BC group
(p = 0.009).
The Brazilian population is characterized by a mixture
of races, which justifies the HWE deviation in the distri-
bution of genetic variants. Thus, the HWE was calcu-
lated based on Caucasian or non-Caucasian races in
both groups, the control group (p = 0.008 and 0.264),
and BC group (p = 0.112 and p = 0.723). The controlCaucasian group presented an unbalanced distribution
of variants (Table 3).
A multiple logistic regression analysis was conducted
to evaluate the association of the hsa-miR-196a2
rs11614913 C/T polymorphism adjusted for interfering
variables as age, race, menarche age, menopausal status,
smoking habits, and first-degree breast cancer family
history. The presence of the TC or TT variants increased
the risk of breast cancer in 50% when adjusted for the
confounding variables (Table 4).
The presence of the hsa-miR-196a2 rs11614913 C/T
polymorphism was not associated with histological
grade (p = 0.522), axillary lymph node positive status
(p = 0.805), or clinical stage (p = 0.670) among breast
cancer patients. On the other hand, histological grade
was negatively associated with age (Pearson correlation:
r = −0.106; p = 0.037) and positively associated with
smoking (Pearson correlation: r = 0.106; p = 0.038). The
Table 3 Genotype distribution in the CT and BC groups
based on races
GROUPS Genotype HWE
CC TC TT
CT Caucasian Count 94 114 66 0.008
% within Group 34.3% 41.6% 24.1%
CT non-Caucasian Count 33 51 30 0.264
% within Group 29.0% 44.7% 26.3%
BC Caucasian Count 83 148 94 0.112
% within Group 25.5% 45.6% 28.9%
BC non-Caucasian Count 11 29 23 0.723
% within Group 17.5% 46.0% 36.5%
HWE: Hardy-Weinberg Equilibrium.
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ciated with a family history of breast cancer (Pearson
correlation: r = 0.190; p < 0.001). The clinical stage of
breast cancer was not associated with the hsa-miR-196a2
rs11614913 C/T polymorphism or demographic variables.
Discussion
The growing interest in evaluating the association be-
tween the hsa-miR-196a2 rs11614913 SNP and develop-
ment of BC [3,4,15-17], along with the lack of studies in
Latin America on this subject, were the foundations for
this study.
Many associations between miRNAs and occurrence
of BC have been demonstrated experimentally. The
understanding of the mechanisms involved in these
associations could establish the use of these markers
(miRNAs) as powerful tools for the prevention and
treatment of BC [9].
MiRNAs are involved in critical biological processes
including development, differentiation, apoptosis, and
proliferation. Genetic polymorphisms of miRNAs (SNPs)
can potentially influence the processing or selection of
miRNA targets. The association between hsa-miR-196a2
rs11614913 SNPs and susceptibility to develop breastTable 4 Multiple logistic regression analysis adjusted for
the interfering variables to evaluate the association
between polymorphism and occurrence of BC
Constant SE OR P
Presence of TC or TT variant 0.406 0.165 1.501 0.014
Age (years) 0.023 0.008 1.024 0.003
Non-Caucasian race −0.786 0.180 0.456 0.000
Age at Menarche (years) 0.021 0.047 1.021 0.660
Menopause (yes or no) −0.523 0.194 0.593 0.007
Smoking (yes or no) −0.192 0.190 0.825 0.311
BC Family history (yes or no) −0.291 0.187 0.748 0.119
Constant −1.244 0.733 0.288 0.090
SE: standard error. OR: odds ratio.cancer have been evaluated by several recent studies
[15,16,18].
Considering the important role of hsa-miR-196a2
rs11614913 in the carcinogenic process of breast cancer,
the present study evaluated the distribution of this
genotype and estimated the risk of the development of
BC in Brazilian women.
Predominance of the TC genotype (heterozygote) was
observed in the subjects in the study and corroborated
the data reported in the literature [15,16,18]. The
analyzed groups in this study were representative of a
miscegenated population (Brazilians) and cannot be
compared with other studied populations. The predom-
inant allele distribution observed in this population did
not diverge from that reported in the literature, despite
the miscegenation, suggesting that the heterozygous
form is the most prevalent worldwide.
Hu et al. observed an increased risk of breast cancer
associated to the TC/CC genotypes with OR of 1.23
(1.02–1.48) when studying an Asian population [15].
Gao et al. conducted a meta-analysis of the hsa-miR-
196a2 distribution that suggested that women with the
CC polymorphic genotype had an increased risk of
breast cancer with OR of 1.30 (1.01-1.68) [19]. Neverthe-
less, the results from these studies remain conflicting
and inconclusive [19]. Conversely, Catucci et al. did
not identify statistical correlations between the presence
of hsa-miR-196a2 rs11614913 in women with breast
cancer and controls in German and Italian populations
[16]. The present study produced different results show-
ing an association between the presence of the T (TC/
TT) allele and increased risk of BC with OR of 1.52
(1.11-2.08); in addition, the results indicate that the CC
(mutant homozygous) polymorphic genotype acted as
a protective factor with OR of 0.61 (0.42-0.89). The
discordant results could be suggestive of the extensive
miscegenation between different ethnic groups in the
Brazilian population, which could lead to increased gen-
etic variability. In a meta-analysis including different
populations, where a statistical rearrangement was per-
formed, the tendency of the hsa-miR-196a2 rs11614913
SNP to act as a protective factor against breast cancer
was observed with OR of 0.83(0.77–1.03) and p = 0.07;
these results corroborate the results observed in the
meta-analysis [16]. Wang et al. observed that the
increased risk of BC associated with the CC genotype
was present in Chinese and Indian women but not in
Caucasian women; the latter being closer to the Brazilian
population than the Asian populations [20].
Conclusions
The results obtained in this study relative to the hsa-
miR-196a2 rs11614913 SNP in the Brazilian population
indicated that the CC polymorphic genotype is
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of the T allele is significantly associated with an
increased risk of BC. Further studies with larger sample
sizes and in populations with similar ethnic background
could contribute in supporting the results presented in
the current study.
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